Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease [2]

New England Journal of Medicine

Volumn 370, Issue 15, 2014, Pages 1459-1460

  De La Torre, Jack C ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BAPINEUZUMAB; SOLANEZUMAB;

ALZHEIMER DISEASE; DISEASE COURSE; DISEASE SEVERITY; HUMAN; LETTER; NEUROFIBRILLARY TANGLE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS;

EID: 84898714277     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1402193     Document Type: Letter

References (4)

1. Karran E, Hardy J. Antiamyloid therapy for Alzheimer's disease - are we on the right road? N Engl J Med 2014;370:377-8.
2. de la Torre JC. Vascular risk factors: a ticking time bomb to Alzheimer's disease. Am J Alzheimers Dis Other Demen 2013; 28:551-9.
3. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:311-21.
4. Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 2001;15: 169-73. (Pubitemid 33117032)